



Abbott India Limited  
Godrej BKC, Plot C-68, "G"Block,  
15-16th Floor, Bandra-Kurla Complex,  
Near MCA Club, Bandra (E),  
Mumbai - 400 051, India

Registered Office:  
3, Corporate Park,  
Sion Trombay Road,  
Mumbai - 400 071, India

Tel: (91-22) 5046 1000/2000  
Fax : (91-22) 5016 9400  
E-mail : webmasterindia@abbott.com  
Website : www.abbott.co.in  
CIN: L24239MH1944PLC007330

## Statement of unaudited results for the quarter ended June 30, 2020

(Rs. in Lakhs except earnings per share)

Particulars	Quarter ended			Year ended
	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
	Unaudited	Audited	Unaudited	Audited
		Refer Note 4		
<b>1 Income</b>				
(a) Revenue from operations	1064,27	961,20	998,89	4093,14
(b) Other income	27,63	28,13	29,60	114,39
<b>Total Income</b>	<b>1091,90</b>	<b>989,33</b>	<b>1028,49</b>	<b>4207,53</b>
<b>2 Expenses</b>				
(a) Cost of materials consumed	125,73	139,27	99,14	451,76
(b) Purchases of stock-in-trade	541,50	486,25	446,84	1802,64
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(57,19)	(69,92)	14,01	61,25
(d) Employee benefits expense	128,48	116,31	120,18	476,11
(e) Finance costs	4,45	2,82	2,03	8,53
(f) Depreciation and amortisation expense	14,10	14,81	14,80	59,61
(g) Other expenses	92,33	150,86	144,54	544,94
<b>Total Expenses</b>	<b>849,40</b>	<b>840,40</b>	<b>841,54</b>	<b>3404,84</b>
<b>3 Profit before tax (1-2)</b>	<b>242,50</b>	<b>148,93</b>	<b>186,95</b>	<b>802,69</b>
<b>4 Tax expenses</b>				
(a) Current tax expense	63,60	36,76	70,80	208,04
(b) Tax adjustment for earlier years	-	-	-	25
(c) Deferred tax expense/(credit)	(1,45)	1,20	(79)	1,47
<b>Total Tax Expenses</b>	<b>62,15</b>	<b>37,96</b>	<b>70,01</b>	<b>209,76</b>
<b>5 Profit for the period (3-4)</b>	<b>180,35</b>	<b>110,97</b>	<b>116,94</b>	<b>592,93</b>
<b>6 Other Comprehensive Income</b>				
Items that will not be reclassified subsequently to Profit or Loss	(1,35)	(2,98)	(80)	(5,40)
Income tax on above	34	75	28	45
<b>Total Other Comprehensive Income, net of tax</b>	<b>(1,01)</b>	<b>(2,23)</b>	<b>(52)</b>	<b>(4,95)</b>
<b>7 Total Comprehensive Income for the period, net of tax (5+6)</b>	<b>179,34</b>	<b>108,74</b>	<b>116,42</b>	<b>587,98</b>
<b>8 Paid-up Equity Share Capital</b> (Face Value of Rs.10 per Equity Share)	21,25	21,25	21,25	21,25
<b>9 Earnings per equity share - Basic/Diluted</b> (of Rs.10/- each) (not annualised)	84.87	52.22	55.03	279.04

**NOTES :**

- 1 The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on August 7, 2020.
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 The financial results for quarter ended June 30, 2020 have been subjected to limited review by the statutory auditors of the Company. The Limited Review Report does not contain any qualifications.
- 4 The figures for the quarter ended March 31, 2020 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year which were only reviewed and not subjected to audit.
- 5 The extended lockdown on account of COVID-19 pandemic has led to a slowdown of demand in some therapeutic areas and resulted in lower sales. The Company continues to ensure uninterrupted supply of products to meet the needs of our customers. The Company's manufacturing operations at Goa are operating at sufficient capacity with adequate measures of social distancing and safety to help ensure a healthy workplace for the employees on-site. Office-based work continues to be conducted remotely. While the national lockdown has been eased in some states, field employees are returning to the field as per the specified government regulations.  
The Management has exercised due care, made reasonable judgements and estimates, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets based on the information available to date, while preparing the financial results as of and for the quarter ended June 30, 2020. The Company continues to closely monitor the situation and will take appropriate measures in an attempt to mitigate any adverse impact.
- 6 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 7 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the Board of Directors of  
Abbott India Limited**

**Place : Mumbai  
Date : August 7, 2020**

**Rajiv Sonalker  
Whole-time Director and CFO  
DIN : 07900178**